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ABSTRACT
Chronic lymphocytic leukaemia (CLL) cells require micro-
environmental support for their proliferation. This can be recapitulated
in highly immunocompromised hosts in the presence of T cells and
other supporting cells. Current primary CLL xenograft models suffer
from limited duration of tumour cell engraftment coupled with gradual
T-cell outgrowth. Thus, a greater understanding of the interaction
between CLL and T cells could improve their utility. In this study, using
two distinct mouse xenograft models, we investigated whether
xenografts recapitulate CLL biology, including natural environmental
interactions with B-cell receptors and T cells, andwhethermanipulation
of autologous T cells can expand the duration of CLL engraftment. We
observed that primary CLL xenografts recapitulated both the tumour
phenotype and T-cell repertoire observed in patients and that
engraftment was significantly shorter for progressive tumours. A
reduction in the number of patient T cells that were injected into the
mice to 2-5% of the initial number or specific depletion of CD8+ cells
extended the limited xenograft duration of progressive cases to that
characteristic of indolent disease. We conclude that manipulation of T
cells can enhance current CLL xenograft models and thus expand their
utility for investigation of tumour biology and pre-clinical drug
assessment.
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INTRODUCTION
Chronic lymphocytic leukaemia (CLL), a malignancy of mature B
cells, is characterised by the dynamic interaction between quiescent
cells in the peripheral blood and cells induced to proliferate by
microenvironmental stimuli in proliferation centres of lymphoid
organs or bone marrow (Damle et al., 2010; Oppezzo and Dighiero,
2013; ten Hacken and Burger, 2014; Zhang and Kipps, 2014). CLL
cells resident in proliferation centres are not readily accessible and
the complex microenvironmental interactions, including those with
antigen-presenting cells and activated T cells (Oppezzo and
Dighiero, 2013; ten Hacken and Burger, 2014), are difficult to
recapitulate in vitro. This seriously hampers the study of CLL
biology and limits pre-clinical assessment of novel therapeutic
agents. To overcome restrictions of in vitro assays, extensive effort
has been invested in development of CLL animal models. Currently,
there are two principal approaches: transgenic CLL murine models
and adoptive transfer of either primary CLL cells or CLL cell lines
into immunodeficient mice (Bertilaccio et al., 2013; Bichi et al.,
2002; Chen and Chiorazzi, 2014; Kasar et al., 2012; Klein et al.,
2010; Santanam et al., 2010).
Transgenic CLL murine models are suitable for assessment of
specific genetic events involved in CLL tumourigenesis (Bertilaccio
et al., 2011, 2013; Chen et al., 2009a,b; Chen and Chiorazzi, 2014;
Hofbauer et al., 2011; Gorgun et al., 2009; Kriss et al., 2012; Reinart
et al., 2013; Santanam et al., 2010; Zanesi et al., 2013) but have
several limitations. Delayed onset of leukaemia (Bichi et al., 2002;
Hofbauer et al., 2011; Klein et al., 2010; Santanam et al., 2010),
differing surface expression of human and murine epitopes (Hu
et al., 2009; Leskov et al., 2013) and incapability to recapitulate the
intratumour CLL clonal diversity that is inextricably linked to both
treatment response and tumour progression (Knight et al., 2012;
Landau et al., 2013; Schuh et al., 2012) all limit the use of these
models for pre-clinical testing of emerging therapies. Consequently,
development and optimisation of primary CLL xenografts that
could potentially reconstitute these natural elements of human CLL
is highly warranted.
Attempts to develop robust primary CLL xenograft models in
NOD/SCID mice deficient in T- and B-cell activity often failed as a
result of a combination of absence of the correct tumour
environment and presence of natural killer immunity in the host
(Dürig et al., 2007; Kobayashi et al., 1992; Shimoni et al., 1999).
The production of more severely immunocompromised mice
[NOD/LtSz-SCID/IL-2γtm1Wjl/SzJ (NSG) and Rag2−/−γc
−/−],
which further lack natural killer activity, has partially overcome
this issue (Bagnara et al., 2011; Bertilaccio et al., 2010; Devereux,
2011; Herman et al., 2013). Recently, the tumour environment has
been addressed and two xenograft models generated (Bagnara
et al., 2011). The models employed NSG mice in combination with
allogeneic supporting cells either to reconstitute the human
haematopoietic system with cord blood-derived CD34+ stem cells
or to supply a component of the microenvironmental stimuli with
antigen-presenting CD14+ monocytes. Subsequent modifications
have been employed in attempts to remove the need for allogeneic
cells (Bertilaccio et al., 2010; Herman et al., 2013). These models
indicated a role for T cells, particularly CD4+, in both the
mediation of CLL engraftment (Bagnara et al., 2011; Devereux,
2011; Dürig et al., 2007; Shimoni et al., 1999) and the resultantReceived 10 April 2015; Accepted 10 August 2015
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CLL cell disappearance with concomitant evidence of lethal graft-
versus-host disease (GvHD) (Bagnara et al., 2011; Devereux,
2011). However, both of the original NSG models (Bagnara et al.,
2011) exhibited limited graft duration, possibly as a result of
associated outgrowth of T cells (Bagnara et al., 2011). Thus, in the
light of emerging therapies that utilise and modulate T cells and
other components of the microenvironment, it is important that the
CLL interactions and T-cell repertoire of patients can be faithfully
modelled, for sufficient duration, to facilitate optimal pre-clinical
in vivo assessment.
In this study, we investigated whether cord blood or monocyte-
supported CLL xenograft models can recapitulate the CLL
biology and T-cell repertoire of patients and whether titration of
autologous T cells prior to xenotransplantation can prolong
engraftment in a highly immunocompromised host, thereby
enhancing the utility of these models. We observed that both
models recapitulate the patient CLL and T-cell phenotype and that
titration of T cells or the CD8+ subset from patients with
progressive tumours prior to xenotransplantation can extend the
duration of CLL engraftment.
RESULTS
CLL xenografts reflect patient-specific CLL features
We employed reported NSG model variants (Bagnara et al., 2011)
in the NOD/Shi-SCID/IL-2Rγctm1sug/Jic (NOG) Mus musculus
Linnaeus 1758 (mouse) strain that were readily available and bred
by our establishment to assess whether xenografts can be
established for a range of CLL biological subtypes. NOG mice
exhibit a similar immunocompromised phenotype to NSGmice and
preliminary studies indicated comparable engraftment kinetics in
both strains (Bagnara et al., 2011). Mice humanised by allogeneic
CD34+ umbilical cord cells or supported by allogeneic CD14+
monocytes as T-cell allo-stimuli (Bagnara et al., 2011) were
injected with 15 CLL peripheral blood mononuclear cells (PBMCs)
representing two broad biological CLL types characteristic of
indolent and progressive stages of disease (Table S1).
Consistent with NSG mice (Bagnara et al., 2011), support with
either CD34+ or CD14+ cells sustained CLL engraftment,
predominantly in murine spleen but also in the bone marrow and
blood of all cases (Fig. 1, Fig. S1). In comparison with previous
studies (Bagnara et al., 2011; Dürig et al., 2007; Herman et al.,
2013), we attained a higher percentage of CLL engraftment. This
could relate to differences in experimental conditions, including
patient sample engraftment heterogeneity, injection site, single cell
isolation method, specificity of CLL markers used for detection,
experimental time points and the mouse strain. Nevertheless, the
cell numbers retrieved from spleens 12 weeks post-injection
(0.75×105 hCD45+CD3− versus 0.6×105 hCD45+CD19+CD5+
CD23+) were comparable (Dürig et al., 2007).
CLL cell proliferation in engrafted spleens was corroborated by
Ki-67 positivity and diminishing carboxyflourescein succinimidyl
ester (CFSE) intensity (Fig. 1C, Fig. S2). Diminishing CFSE
intensity indicated that, at termination, very few non-proliferating
CLL cells were present in either the cord blood model or the
monocyte model (peripheral blood, 4.1±3.2% versus 0.0±0.0%;
spleen, 0.6±0.4% versus 0.3±0.3%; bone marrow, 0.6±0.3% versus
0.0±0.0%; see Fig. S2). Engrafted B cells originated from the
malignant rather than the non-malignant compartment, as evidenced
by a lack of Epstein–Barr virus (EBV)-encoded RNA (EBER)
expression (Fig. 1D) and retention of leukaemic-specific genotypic
features (Fig. 1E,F). The architecture observed in patients was
reproduced by engrafted CLLs. Progressive CLL cells resembled
proliferation centres in lymph nodes of patients and in NSG
xenografts (Bagnara et al., 2011), with Pax5+ CLL cells surrounded
by human CD3+ T cells. Indolent CLL B cells were diffusely
distributed, consistent with the reduced proliferation levels observed
in patients (Fig. 1G) (Giné et al., 2010). Also, in similarity with the
scenario in patients (Ghia et al., 2002; Jadidi-Niaragh et al., 2013;
Nunes et al., 2012), T cells appear to play a role in CLL progression
and, akin to NSG xenografts (Bagnara et al., 2011), the demise of
NOG animals was associated with an increasing proportion of
T cells (Table S2). In the monocytic model, a minimal proportion
of splenic T cells was observed for the progressive CLL, QEo24
(Fig. 1B; Table S2). This could be a feature of this particular CLL,
characterised by rapid engraftment, where demise of the animals
occurred prior to expansion of splenic T cells but with evidence of
TRANSLATIONAL IMPACT
Clinical issue
Chronic lymphocytic leukaemia (CLL) is currently an incurable
malignancy of mature B cells, with a heterogenic clinical course and
variable response to treatment. It is characterised by the dynamic
interaction between quiescent cells in the peripheral blood and cells that
are induced to proliferate by microenvironmental stimuli in lymphoid
organs or bone marrow. These proliferation sites are difficult to access
and the activating stimuli difficult to recapitulate in vitro. To address this
deficiency, both transgenic and primary CLL animal models have been
developed. The former express murine epitopes and cannot recapitulate
intratumour clonal diversity; the latter are poorly characterised and of
limited duration owing to T-cell outgrowth. These issues seriously
hamper the study of CLL biology and limit the preclinical assessment of
novel therapeutic agents. A better understanding of the interaction
between B-CLL cells, T cells and other microenvironmental factors, and
of the impact of this interaction on disease progression, subclonal
diversity and treatment response, would direct the identification of novel
treatments. Also, patient-relevant in vivo models of sufficient duration
that are able to recapitulate the subclonal complexity of CLL are an
essential component of preclinical drug assessment and can inform
tailored treatment regimens.
Results
This work provides an in-depth analysis of T cells in primary CLL
xenografts and describes a simple adaptation of current models that
enables long-term analysis of CLL progression. The authors show, for
the first time, that T-cell numbers affect the course of CLL xenografts in
alymphoid mice. Specifically, minimisation of T cells, particularly of the
CD8+ subset, in aggressive samples extended graft duration to that of
indolent (non-aggressive) xenografts. The xenograft models retained
several biological properties of primary leukaemias, including disease
course, T-cell repertoire and microenvironmental interactions (B-cell
receptor signalling and T-cell engagement). All these observations were
evident in both of the xenograft models assessed, i.e. CLL xenografts
generated by injection of either allogeneic umbilical-cord blood-derived
cells or allogeneic monocytes.
Implications and future directions
This work highlights the importance of T cells in CLL progression. The
T-cell minimisation strategy expands the duration of aggressive CLLs, for
which there is an urgent need for new treatment regimens. Thus, this
study provides a patient-relevant platform to investigate the role of
T cells, tumour progression and efficacy of therapeutic agents, including
long-term treatment modalities in preclinical settings. In addition, it helps
gain insights into various tumour niches, which are difficult to access in
patients. Thus, three rapidly developing areas of interest, namely T-cell
biology, new treatment regimes and subclonal diversity, will all
benefit from this system that recapitulates CLL natural disease and
environment.
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T-cell outgrowth in the peripheral blood and bone marrow
(Table S2).
In contrast to the NSG host (Bagnara et al., 2011), engrafted
splenic B cells were present when NOG mice succumbed (Fig. 1).
Outgrowing T cells in the cord blood model displayed a variable
degree of T-cell chimerism: a mixture of patient and cord blood-
derived human T cells (Fig. S3). We observed no evidence of
GvHD: engrafted animals did not present with inflammation of the
skin or eyes or T-cell infiltration of liver as observed in NSG mice
(Fig. S4) (Bagnara et al., 2011). Animal pallor suggested bone
marrow failure as a result of replacement of murine haematopoiesis
by human leukaemic or T cells as the cause of death. This was
evidenced by variable bone marrow replacement with human
CD45+ cells (10.9-75.4%) in more than 50% of animals (49/80). In
the majority of cases (43/49), B cells outnumbered T cells (B cells
8.4-68.5%, mean±s.e.m. 30.9±2.7%; T cells 0.1-22.5%, 4.8±0.8%),
Fig. 1. CLL xenografts of a range of biological subtypes recapitulate patient-specific CLL features. (A) The proportion of B cells (CD3−) or T cells (CD3+)
that comprise the percentage of engrafted human lymphocytes (hCD45+) of total extracted cells at termination, in murine spleen or bone marrow (BM), upon
engraftment of indolent (4 CLL, 8 mice, 7.1±0.9×107 PBMC/animal) or progressive (5 CLL, 13 mice, 2.4±0.6×107 PBMC/animal) CLLs in the cord blood model.
(B) The proportion of B or T cells that comprise the percentage of engrafted human lymphocytes (hCD45+) of total extracted cells upon engraftment of indolent (2
CLL, 3 mice, 6.8±3.2×107 PBMC/animal) or progressive (1 CLL, 4 mice, 0.5±0.0×107 PBMC/animal) CLLs in the monocyte model. The majority of the remainder
of the total cell population (hCD45−) is of murine origin, possibly with a few human cells expressing undetectable levels of hCD45, including negligible levels of
natural killer cells. (C) Representative immunohistological micrographs of CLL engrafted murine spleens depicting expression of Ki67 in proliferating human
CD20+ B cells and CD3+ T cells (examples indicated by white arrows). Images were captured by the Zeiss Zen780 confocal microscope (Cambridge,
Cambridgeshire, UK) at 40× magnification prior to article production. (D) Engrafted cells were not derived from normal B cells latently infected with EBV (inset
shows positive control). (E) Representative example of 11q−/+ cell engraftment identified by FISH. Normal cells contain two copies each of chromosome 10 (red
control spots), chromosome 12 (green spots) and 11q (yellow spots, white arrows). The 11q−/+ cells in the right handmicrographs only contain a single 11q allele.
Cells were visualised at 100× magnification prior to article production. (F,G) Representative immunohistological micrographs of CLL engrafted murine spleens
depicting expression of (F) ATM and (G) markers of B-CLL cells (Pax5) and T cells (CD3). (D,F,G) Images were captured by the Leica DMLB microscope with a
Leica DFC320 camera (Milton Keynes, Buckinghamshire, UK) at 10× magnification prior to article production. Engraftment levels were compared using one-way
analysis of variance (ANOVA) with Tukey post-test (A) or a two-tailed t-test (B) and statistical significance denoted by ‡P≤0.05 (hCD45 engraftment). Scale bars:
20 µm (C), 50 µm (D,F,G), 5 µm (E).
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but, occasionally (6/49 animals), T cells were the dominant
population (T cells 9.2-35.8%, 18.3±4.3%; B cells 1.5-10.2%,
6.2±1.2%). Also, unlike the NSG models (Bagnara et al., 2011), we
observed significantly shorter overall survival (OS) of animals
engrafted with progressive leukaemias compared with those
receiving indolent CLL samples (median survival 41 versus
180.5 days) (Fig. 2A). This was consistent with the higher
engraftment levels attained by progressive leukaemias (Fig. 1A,B).
Thus, the kinetics of CLL engraftment in NOGmice broadly reflects
the disease course in CLL patients.
There was low inter-assay variability in OS and engraftment
levels after administration of the same CLL in different experiments
(C.E.O., unpublished). Additionally, neither OS nor engraftment
levels bore any correlation to the injected number of CLL PBMCs,
irrespective of whether xenografts were derived from patients with
indolent or progressive disease (Fig. 2B,C). Finally, similarly to CLL
cells in lymph nodes (Krysov et al., 2012), phosphorylated ERK1/2
(p-ERK) and phosphorylated-phospholipase Cγ2 (pPLCγ2) were
detected in engrafted CLL cells (Fig. 2D). Although not specific for
B-cell receptor (BCR) signalling, taken together, detection of these
markers was consistent with the notion that the BCR was activated
within the engrafted CLL cells (Herman et al., 2014).
CLL xenografts recapitulate patient T-cell subset
proportions
The interaction between T cells and CLL cells is an important aspect
of CLL biology (Jin et al., 2010; Kalscheuer et al., 2014; Piper et al.,
2011; Riches et al., 2013; Sakuishi et al., 2010; Sumida et al., 2013;
Zhou et al., 2011); thus, an understanding of their interdependence
in the xenograft model would improve its utility. To address this, we
determined the subtypes of engrafted splenic T cells.
In the cord blood model, terminally engrafted T cells were
predominantly of CD4+ subtype, regardless of the biological
properties of the CLL and the length of CLL engraftment. The
majority of T-cell subsets observed in patients could be detected in
CLL xenografts in similar proportions, except for significantly
Fig. 2. CLL xenografts recapitulate CLL kinetics and engage the BCR. (A) Overall survival (OS) of NOG mice after engraftment of indolent (5 CLL, 12 mice,
5.0±1.1×107 PBMC/animal) or progressive (5 CLL, 14mice, 3.0±0.7×107 PBMC/animal) CLLs in the cord bloodmodel. Correlations between the initial number of
injected patient PBMC and (B) the final level of splenic CLL cell (hCD45+CD3−) engraftment or (C) OS with either CD14+ support (monocyte) or prior CD34+ cell
humanisation (cord blood) for indolent or progressive cases. (D) Representative immunohistological micrographs of CLL engrafted murine spleens depicting
expression of p-ERK and pPLCγ2 in CD20+ B cells (examples indicated by white arrows) consistent with activation of the BCR signalling pathway. Images of
p-ERK were captured by the slide visual Olympus Dotslide microscope (Southend-on-Sea, Essex, UK) at 20× magnification prior to article production. Scale bar:
50 µm. The virtual slide images (VS120) were analysed byOlyVIA (free software, www.olympus.software.informer.com). Images of pPLCγ2 were captured by the
Zeiss LSM 510 Meta confocal microscope (Cambridge, Cambridgeshire, UK) at 63× magnification prior to article production. Scale bars: 10 µm. Statistical
significance denoted by **P≤0.01.
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(P≤0.05) elevated levels of T-regulatory cells (CD4+CD25+FoxP3+),
typically associated with CLL progression (Jadidi-Niaragh et al.,
2013) (Fig. 3A,B). Ratios of CD4 to CD8 were within the normal
range for CLL (Nunes et al., 2012) and insignificantly altered from
that of the patient PBMCs, thus remained characteristic of patient
disease status (Fig. S5). The slight discrepancies between patient
PBMCs and xenograft spleens were in accordance with observations
in the NSG models suggesting that the CD4:CD8 ratio differed
between murine peripheral blood and spleen (Bagnara et al., 2011).
Thus, irrespective of the T-cell origin (patient-derived, cord blood-
derived or a mixture) in the cord blood model (Fig. S3), the patient
T-cell subset proportions were retained (Fig. 3B and Fig. S5).
A bi-weekly sequential cull of one animal from both the cord
blood (C.E.O., unpublished) and monocyte models revealed that
the autologous T-cell repertoire was dynamic and continually
changing. The repertoire observed in patients’ peripheral blood was
gradually acquired in murine spleens within 10-12 weeks, whereas
at all other time-points, the proportion of splenic CD8+ cells
differed significantly (P≤0.05) from patient PBMCs. This
presented as an initial preponderance of splenic CD4+ cells with
gradual expansion of T-regulatory cells (CD4+CD25+FoxP3+),
followed by expansion prior to a decline in CD8+ cells (Fig. 3C).
Finally, human CD4+ T cells were revealed to be within the splenic
proliferation centres surrounded by CD8+ T cells for progressive
CLL xenografts, whereas a diffuse distribution of both subsets was
observed for indolent CLL xenografts (Fig. 3D).
Engrafted T cells display a dysfunctional phenotype
A T-cell exhaustion phenotype previously reported in patients
(Riches et al., 2013) was also evident in cord blood-supported
Fig. 3. Engrafted T cells reflect the patient subtype repertoire. T cells derived from terminally engrafted spleens from the cord blood model recapitulate the
T-cell subtype characteristics of CLL cells. (A) Representative immunohistological micrographs depicting engrafted human T-cell subtype marker expression.
Images were captured by the Leica DMLB microscope with a Leica DFC320 camera (Milton Keynes, Buckinghamshire, UK) at 10× magnification prior to article
production. (B) FACS analysis quantification and comparison of T-cell subsets in xenograft-derived splenic human cells CD8+, CD4+ and CD4+CD25+ (9 CLL, 20
mice) and CD4+CD25+FoxP3+ (5 CLL, 5 mice) and in patient samples (input) CD8+, CD4+ (11 CLL), CD4+CD25+ (10 CLL) and CD4+CD25+FoxP3+ cells (9 CLL).
(C) Engraftment kinetics of the various patient-derived T-cell subsets were followed by analysis of sequentially sacrificed animals. Mice with CD14+ monocyte
support were injected with PBMCs from one of three CLL patients (n=8 mice/CLL). A single animal from each cohort was sacrificed bi-weekly for 20 weeks and
splenic cell composition analysed by FACS. Terminal engraftment had not been attained by this time-point. (D) Representative immunohistological micrographs
illustrating the differing splenic distribution and contact between engrafted human CD19+ CLL cells (red) and either CD4+ or CD8+ T cells derived from indolent or
progressive CLLs. Images were captured by the Nikon Eclipse E400 microscopewith a Nikon DS-Fil camera linked to Nikon Digital Sight Capture (Kingston upon
Thames, Surrey, UK) at 10× magnification prior to article production. Subtype proportions were compared using a two-tailed t-test (B), one-way ANOVA with
Dunnett’s post-test versus Input or two-way ANOVA with Bonferroni post-test versus Week 2 (C); *P≤0.05 (versus Input). Scale bars: 50 µm.
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xenografts. Of note, the PD-1+ expression levels of the input
samples were low (13.0-36.3% of CD4+; 3.1-14.7% of CD8+) but
fell within the broad range reported for CLL PBMCs, which spans
and encompasses the healthy donor range (Brusa et al., 2013;
Gassner et al., 2014; Nunes et al., 2012; Riches et al., 2013; te Raa
et al., 2014). However, engrafted splenic cells displayed high
expression of the exhaustion markers human (h)PD-1, hCD160 and
hCD244 (Fig. 4A). Further assessment utilising the monocyte
model, in which all T cells can only be patient-derived, confirmed
an exhaustion phenotype (TIM3+PD-1+) (Crespo et al., 2013; Jin
et al., 2010; Sumida et al., 2013; Zhou et al., 2011). However,
akin to the CD4:CD8 ratio discrepancies observed in the NSG
model (Bagnara et al., 2011), engrafted splenic proportions were
skewed towards a significantly (P≤0.01) greater proportion of
exhausted T cells (TIM3+PD-1+), with concomitant fewer anergic
(TIM3−PD-1+) and senescent or functional (TIM3+/−PD-1−)
T cells compared with patient PBMCs (Fig. 4B). The observed
T-cell phenotype differences between patient PBMCs and engrafted
splenic T cells could be a result of their interaction with tumour cells
in murine spleens or merely a side effect of xenotransplantation.
However, studies using the Eµ-TCL1 transgenic adoptive transfer
mouse model have demonstrated that the tumour, rather than
transplantation into a secondary recipient, is responsible for the
exhausted phenotype of splenic T cells (Gassner et al., 2015;
McClanahan et al., 2015).
Also, in contrast with the predominant effector memory (EM) and
effector memory RA (TEMRA) phenotypes observed in the
peripheral blood of CLL patients (Riches et al., 2013), terminal
engrafted splenic T cells bore a predominantly naive or central
memory (CM) phenotype with significantly less (P≤0.01) EM and
TEMRA for all T-cell subsets (Fig. 4C); a repertoire that is indicative
of anergy and thus tolerance (Crespo et al., 2013). Thus, in similarity
to the scenario in patients, CLL cells appear to influence the T-cell
phenotype in CLL xenografts. The phenotypic discrepancies
between T cells from patient PBMCs and engrafted spleens could
be attributed to the dynamic and varying nature of T-cell interactions
in diverse locations and microenvironments (Jin et al., 2010;
Sakuishi et al., 2010; Sumida et al., 2013; Zhou et al., 2011).
Fig. 4. Engrafted T cells display a dysfunctional phenotype typical of CLL. (A) Representative immunohistological micrographs depicting expression of the
exhausted markers hPD-1, hCD160 and hCD244 in spleens engrafted using the cord bloodmodel in comparison with healthy human tonsils (inset). Images were
captured by the slide visual Olympus Dotslide microscope (Southend-on-Sea, Essex, UK) at 20× magnification prior to article production. Scale bars: 50 µm.
The virtual slide images (VS120) were analysed by OlyVIA (free software, www.olympus.software.informer.com). (B) FACS analysis demonstrating the T-cell
expression of markers of exhaustion (TIM3+ PD-1+), anergy (TIM3− PD-1+), senescence (TIM3+ PD-1−) and normal function (TIM3− PD-1−) (Crespo et al., 2013)
in the monocyte model (2 CLL, 5 mice) and patient PBMCs (3 CLL). (C) FACS quantification of naive (CCR7+ CD45RA+), CM (CCR7+ CD45RA−), EM (CCR7−
CD45RA−) and TEMRA (CCR7− CD45RA+) human T cells from either injected patient PBMCs (3 CLL) or xenograft-derived splenic cells (3 CLL, 6 mice).
(D) Quantification by FACS analysis of CD19+ B-CLL cells following co-culture of splenic T cells with B-CLL cells at a ratio of 3:1 reveals a tolerance to the
autologous input B cells (n=3). Data was normalised to the number of surviving B cells after culture of CD19+ B-CLL cells in the absence of extraneous T cells
(B-CLL alone). Data were compared using one-way ANOVA with Tukey post-test and statistical significance versus input (B,C) or B-CLL alone (D) denoted by
**P≤0.01, ***P≤0.001.
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We speculated that dysfunctional human T cells recovered from
the xenografts are unlikely to exhibit anti-CLL activity. Indeed,
upon in vitro co-incubation of engrafted human splenic T cells with
autologous CLL cells, the level of surviving CLL cells increased,
albeit not significantly, potentially indicating a protective effect of
these T cells. In contrast, the T cells retained limited reactivity
towards allogeneic CLL cells (Fig. 4D). This, in combination with
absence of GvHD (Fig. S4), is consistent with T-cell anergy
(tolerance of self and host with retention of some reactive activity).
This concurs with a report indicating tolerance of engrafted human
T cells towards murine HLA types and concurrently injected
allogeneic human cells as a result of T-cell anergy (Kalscheuer
et al., 2014).
Together, these results indicate that engrafted splenic T cells
predominantly express exhaustive phenotypic markers. However,
features of anergy (proliferation, tolerance of host and autologous
cells with retention of limited allogeneic functional activity) and
senescence (TIM3+/−PD-1−) are also evident. Thus, in similarity to
cells from CLL patients, engrafted T cells are dysfunctional,
composed of co-existing populations in various states and
predominantly exhaustive, but also anergic and possibly senescent.
Controlled depletion of autologous T cells expands the
window of CLL engraftment of progressive CLLs for
treatment evaluation
It has been reported that complete T-cell depletion prevents
engraftment (Bagnara et al., 2011). Thus, we hypothesised that
reduction of T cells to a minimal number sufficient to provide
growth stimuli for CLL cells could delay the onset of rapid T-cell
proliferation and consequently prolong CLL engraftment for
treatment evaluation.
To test this hypothesis, autologous CD3+ T cells were titrated
prior to xenotransplantation. Mice injected with 2-5% of patients’
initial T-cell population (7-25 T cells per 1×104 B cells) survived
significantly (P≤0.05) longer than those with either 10-25% or the
full complement of T cells (35-667 T cells per 1×104 B cells)
(median survival 76, 41 and 37 days; respectively) (Fig. 5A).
Prolonged survival of mice injected with T-cell-depleted PBMCs
was not a result of differing numbers or variable compositions of
injected cells nor lack or loss of CLL engraftment. Input cell number
had no impact on OS or engraftment levels (Fig. 2B,C). Also, with
the exception of T cells that were manipulated, input compositions
did not differ between the cohorts as CLLs were matched between
them. The level of B-CLL engraftment was not significantly
affected in spleens from terminally unwell animals injected with the
same tumours following T-cell depletion (Fig. 5B,D; Table S2).
However, titration of T cells to 2-5% significantly reduced the level
of T cells and, thus, total lymphocyte (hCD45+) engraftment in this
cohort (Fig. 5B). The effect of T-cell depletion upon animal
survival was most significant (P≤0.05) among the short-lived
xenografts obtained from progressive CLLs (Fig. 5C,D). Thus,
T-cell manipulation extended the disease course of progressive CLL
xenografts to that of indolent CLL, indicating an important role of
T cells in CLL progression. Confirmation that T-cell manipulation
could be used as a universal approach to prolong CLL engraftment,
irrespective of the CLL xenograft model, was obtained by
application of the same T-cell reduction approach in the
monocyte model. Again, a trend towards increased survival upon
reduction in T-cell number was observed (Fig. 5E).
Time-courses provided evidence that prolonged OS of engrafted
animals following T-cell depletion was not a result of delayed CLL
proliferation and that the duration of CLL engraftment was
expanded. A bi-weekly sequential cull, over 20 weeks, of paired
mice with progressive CLL xenografts, with and without T-cell
restriction, revealed no significant difference in splenic CLL
engraftment kinetics (Fig. 5F, Fig. S6). However, T-cell
restriction delayed the appearance of T cells (Fig. 5F, Fig. S6;
Table S2). The fluctuation in T-cell numbers through the time-
course highlights the spatio-temporal dynamic nature of their
interaction with CLL cells (Fig. 5F). Analogous with the
dysfunctional nature of engrafted T cells (Fig. 4), the total number
of engrafted B cells populating the spleen did not diminish upon the
appearance of T cells (Fig. 5F; Fig. S6, right-hand panels). Also,
splenic CLL engraftment was sustained following prior T-cell
depletion, as evidenced by fewer T cells present at termination and a
concomitant larger B-cell population. CLL cells retained the
lymphoma morphology and BCR signalling in T-cell restricted
xenografts, indicating that the depletion procedure did not abrogate
CLL cell function. The abundance of CLL cells in response to T-cell
depletion indicates that the majority of cells engaging the BCR were
CLL rather than T cells (Fig. 5G).
We conclude that a reduction in the number of patients’ T cells
to ≤5% of the initial population prolongs CLL engraftment,
particularly for progressive tumours, whilst retaining CLL function
and engagement in murine tissues. Our data support a
xenotransplantation model where CLL cells only require a
restricted number of T cells for their proliferation.
CD8+ subsets influence the kinetics of CLL engraftment
Finally, the interaction between specific T-cell subsets and
engrafted CLLs was investigated. The numbers of CD4+ and
CD8+ T cells from PBMCs of patients with progressive disease were
reduced prior to xenotransplantation. As observed for CD3+
reduction, specific reduction of CD8+ cells significantly (P≤0.05)
prolonged CLL engraftment and OS of engrafted mice (Fig. 6A;
Table S2). In contrast, reduction in CD4+ cell numbers had no
significant impact. Time to onset of T-cell proliferation differed
between the various depletion groups and coincided with the demise
of the graft, corroborating a link between T-cell outgrowth and
overall survival (Table S2). Even depletion of CD3+ cells, which
incurred a profound extension of OS, only resulted in an
insignificant reduction in terminal splenic engraftment levels
(Fig. 6B).
DISCUSSION
The nature of the stimulus that drives T-cell proliferation during
CLL xenotransplantation remains unknown. However, we observed
significantly faster kinetics of both CLL and T-cell proliferation in
progressive CLL xenografts, suggesting that CLL cells from these
patients exert a positive influence on T-cell proliferation. Consistent
with this notion, our findings indicate that a minimal fraction of
patients’ T cells (≤5%), as few as 7 T cells per 1×104 B cells, is
sufficient to support CLL proliferation. Also, engrafted T cells
gradually acquire the patient’s T-cell repertoire, both in terms of the
subset frequency and dysfunctional phenotype. This phenomenon
was irrespective of T-cell chimerism, suggesting that CLL cells have
the ability to shape their microenvironment and influence both the
phenotype and proliferation of T-cell populations of different origin
in diverse microenvironments. Our results suggest that an
interaction between CLL cells and the CD8+ T-cell subset may be
of particular importance as depletion of the CD8+ cells prior to
xenotransplantation prolongs engraftment of biologically
progressive CLLs, extending it to that of indolent CLL
xenografts. Further studies are required to determine the temporal
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Fig. 5. Controlled depletion of autologous T cells sustains B-cell engraftment and expands the window of CLL engraftment in progressive CLLs.
To determine the effect of T-cell manipulation on CLL engraftment kinetics, mice were injected with CLLs from which the T cells (CD3+) had been titred out
to various levels. There was no significant variation in the number of injected PBMCs or B cells between any of the groups. (A) OS of animals injected with
the same 3 CLL PBMCs containing 100% T cells (18×104 to 230×104 T cells, 6 mice, 3.2±0.8×107 PBMC/animal), 10-50% T cells (4.55×104 to 115×104
T cells, 7 mice, 3.4±0.8×107 PBMC/animal) or 2-5% T cells (0.91×104 to 4.6×104 T cells, 7 mice, 3.4±0.8×107 PBMC/animal) of their initial T cells. (B) The
proportion of B cells (CD3−) or T cells (CD3+), comprising the percentage of engrafted splenic human lymphocytes (hCD45+) of total extracted cells, at
graft termination of animals administered with CLL PBMCs titred to 100% T cells (2 CLL, 3 mice, 5.0±0.0×107 PBMC/animal), 10-50% T cells (3 CLL, 5
mice, 4.3±0.7×107 PBMC/animal) or 2-5% T cells (3 CLL, 6 mice, 3.8±0.8×107 PBMC/animal) was monitored by FACS in the cord blood model. (C) OS of
animals engrafted with five progressive (12 mice, 2.7±0.8×107 PBMC/animal) or four indolent (8 mice, 7.1±0.9×107 PBMC/animal) CLLs in comparison
with their T-cell depleted counterparts: CD3 dep progressive (12 mice, 2.5±0.5×107 PBMC/animal, 15±5% T cells remaining) or CD3 dep indolent (8 mice,
6.4±0.8×107 PBMC/animal, 25±10% T cells remaining) CLLs. (D) The proportion of B cells (CD3−) and T cells (CD3+), comprising the percentage of
engrafted splenic human lymphocytes (hCD45+) of total extracted cells, at graft termination of mice engrafted with indolent CLLs (4 CLL, 6 mice,
7.8±0.7×107 PBMC/animal), after T-cell depletion (3 CLL, 6 mice, 5.9±1.0×107 PBMC/animal, 30±11% T cells remaining) and progressive CLLs (4 CLL, 8
mice, 3.4±1.1×107 PBMC/animal), depleted of T cells (5 CLL, 11 mice, 2.6±0.6×107 PBMC/animal, 15±5% T cells remaining) in the cord blood model was
quantified by FACS analysis. No significant variation was found between any of the groups or between the level of T-cell depletion. (E) The monocyte
model was also used to follow the OS of mice engrafted with CLL PBMCs containing 100% (1 CLL, 3 mice, 4.0×107 PBMC/animal) or 2-5% (1 CLL, 3
mice, 4.0×107 PBMC/animal) of patients’ T cells. (F) Engraftment kinetics were followed by analysis of sequentially sacrificed animals. Cord blood cell
humanised mice were injected with PBMCs from one of two progressive CLL patients with (n=8 mice/CLL, 0.2×107 to 2×107 PBMC/animal, 17±12% T cells
remaining) and without (n=8 mice/CLL, 0.1×107 to 0.3×107 PBMC/animal) prior reduction of patient T cells. A single animal from each cohort was
sacrificed bi-weekly for 20 weeks and splenic cell composition analysed by FACS. Terminal engraftment had not been reached by this time-point.
(G) Representative immunohistological micrographs of cord blood xenograft spleens with and without prior depletion of T cells, at graft termination: B cells
(Pax5+, CD5+), T cells (CD3+, CD5+), BCR signalling (dual p-ERK+/CD5+ stain). Images were captured by the Leica DMLB microscope with a Leica
DFC320 camera microscope (Milton Keynes, Buckinghamshire, UK) at 10× magnification prior to article production. Scale bars: 50 µm. Engraftment and
input levels were compared using one-way ANOVA with Tukey post-test (B,D), one-way ANOVA with Dunnett’s post-test versus Input or two-way ANOVA
with Bonferroni post-test versus Week 2 (F). Statistical significance is denoted by *P≤0.05 (A,C), †,‡P≤0.05, ††,‡‡P≤0.01 (B; versus Week 2) († T cell,
‡ hCD45 engraftment).
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dynamics of the engrafted T-cell repertoire in various murine tissue
compartments and identify when it most closely resembles that of
patients’ lymph nodes.
Our findings are in agreement with previous reports showing
that, in patients, CLL cells can modify the T-cell environment
(Ghia et al., 2002; Jadidi-Niaragh et al., 2013; Piper et al., 2011;
Yang et al., 2009), induce regulatory T-cell proliferation (Gowda
et al., 2010) and elevate CD8+ T cells during disease progression
(Nunes et al., 2012). This supports the notion of a possible feedback
loop whereby CLL cells stimulate expansion of regulatory and
CD8+ T cells, which in turn reciprocate by supporting CLL
proliferation. Our findings differ from observations in early CLL
models in NOD-SCID mice, which suggested that partial restriction
of T cells could enhance CLL engraftment of indolent but not
aggressive CLL cases (Shimoni et al., 1999). Also, CLL
xenotransplantation of the highly immunocompromised NSG
murine host indicated that T cells are indispensable for
engraftment of all subtypes of CLL but that depletion of the
CD8+ subset does not affect engraftment (Bagnara et al., 2011).
These incongruences could reflect differences in the animal strain
employed and in experimental conditions.
In CLL xenograft models, human T cells serve two functions: to
enable CLL engraftment and to support CLL proliferation. To
distinguish between these two roles it would be of interest
to manipulate specific T-cell subtypes, post-engraftment, by
administration of appropriate antibodies. In addition, combination
with a more in-depth characterisation of the T-cell repertoire would
greatly enhance our knowledge of their role in CLL biology and
therapeutic response. It would be of particular interest to investigate
the role of PD-1-expressing T cells in CLL, given the potential for
treating multiple myeloma by targeting PD-1 (Atanackovic et al.,
2014) and the promising clinical response of solid tumours to anti-
PD-1 treatment (Topalian et al., 2012). Nevertheless, the conclusion
from this study suggests that CLL xenografts recapitulate the T-cell
repertoire observed in patients and therefore represent a useful tool
for studying the effects of a wide range of compounds, including the
most recently developed immunotherapies.
The duration of a CLL xenograft is a crucial component of in vivo
assessment of various targeted treatments. The cytotoxic effect of
compounds such as DNA damaging agents or antibodies directed
against CLL cells can be demonstrated in a relatively short period of
time. However, the impact of agents that rely on gradual
accumulation of DNA damage (DNA repair inhibitors) or those
that require prolonged inhibition of pro-survival signalling (BCR
inhibitors) demand extended duration of the CLL graft.
Additionally, xenograft duration could be crucial during
assessment of drug impact at the subclonal level, particularly to
measure eradication of a specific, refractory CLL subpopulation.
In this study, we show that xenotransplantation of primary CLL
cells in a highly immunodeficient host can be improved by
minimising the number of autologous T cells. Profound depletion
of autologous T cells expanded the window of engraftment for
progressive CLL tumours without affecting the CLL phenotype.
Markers consistent with BCR signalling were retained in xenografts,
irrespective of T-cell depletion, and proliferation of CLL subclones
with specific cytogenetic abnormalities such as 11q deletion was
unaffected by limiting T cells (C.E.O., unpublished). Thus,
xenotransplantation with restricted autologous T-cell numbers has
the potential to enhance the application of CLL xenograft models. It
is tempting to speculate that such enhanced kinetics of
xenotransplantation could provide an attractive model for studying
the biology of primary CLL progression, an advantage that is
currently provided only by transgenic murine CLLmodels. The issue
remains that these models, particularly the cord blood xenografts, are
imperfect artificial CLL systems incorporating allogeneic cells.
Nevertheless, they still provide a more natural environment than can
be modelled either in vitro or in transgenic murine models.
Although the retention of the 11q and ATMgenotypes and lack of
latently EBV-infected healthy B cells indicate that the majority of B
cells in these xenografts were tumour-derived, it is plausible that in
similarity to T cells, B-cell chimerism could occur in the cord blood
model (Bagnara et al., 2011). Further studies are necessary to
address this possibility. To some extent, the confounding effect of
two hematopoietic systems can be surmounted by utilisation of the
monocyte model or CFSE labelling of CLL PBMCs. However, as
CFSE labelling declines with each cell cycle this approach is only
applicable in short-term studies. Alternatively, distinguishing
between the two human haematopoietic systems can be achieved
by use of a CLL-specific marker, such as the application
of mismatching HLA types of CLL patients and cord blood cells.
We believe further optimisation of the variants of CLL
xenotransplantation is highly warranted because, despite their
weaknesses, each model has the potential for a very specific
application. The allogeneic cord blood humanisation model
possesses an advantage in addressing the impact of new
compounds in the context of the normal human hematopoietic
Fig. 6. Specific depletion of the CD8+ T-cell subset expands the window of CLL engraftment of progressive CLLs. (A) OS and (B) the proportion of B
cells (CD3−) or T cells (CD3+) that comprise the percentage of engrafted splenic human lymphocytes (hCD45+) of total extracted cells at termination
following adoptive transfer of progressive CLLs from which specific T-cell subsets had been depleted in the cord blood model (non-depleted, 4 CLL, 11 mice,
3.0±0.8×107 PBMC/animal; CD3 depleted, 4 CLL, 11 mice, 2.7±0.5×107 PBMC/animal, 12±5% T cells remaining; CD4 depleted, 2 CLL, 4 mice, 6.0±2.3×107
PBMC/animal, 33±10% CD4+ cells remaining; CD8 depleted, 2 CLL, 3 mice, 7.3±2.7×107 PBMC/animal, 0±0% CD8+ cells remaining). No significant difference
was found between the levels of subset depletion. Engraftment and depletion levels were compared using one-way ANOVA with Tukey post-test. Statistical
significance is denoted by *P≤0.05, **P≤0.01.
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system as a result of its ability to simultaneously monitor their effect
on both human non-tumour and leukaemic cells. The allogeneic
monocyte support model provides an opportunity to address
immunological aspects of CLL biology.
In summary, we show that duration of CLL xenografts can be
tailored by manipulation of autologous T cells. This adaptation
broadens their utility, particularly for progressive CLL cases,
enabling research into the T-cell biology of CLL and assessment of
the efficacy of novel treatments, including immunotherapies and
those that target the interaction of CLL with the microenvironment.
One can envisage a scenario where, by using such a personalised
CLL xenograft model, together with new methodologies such as
next generation sequencing and single cell analysis, the best
combination of compounds targeting different CLL subclones can
be easily designed.
MATERIALS AND METHODS
Peripheral blood and cord blood samples
CLL and fresh umbilical cord blood samples were collected from local
hospitals. Analysis of IGHV, ATM and TP53 status was performed as
described previously (Skowronska et al., 2012; Stankovic et al., 2002).
Blood samples for isolation of CD14+ monocytes were donated by healthy
volunteers. Studies were approved by the UK National Research Ethics
Service Committee West Midlands – Solihull and performed in accordance
with local ethical guidelines. Written informed consent was obtained from
all patients and healthy donors.
Cell separation and CFSE staining
PBMCs were enriched for CD14+ cells using RosetteSep™ Human
Monocyte Enrichment Cocktail (STEMCELL, Manchester, Greater
Manchester, UK). PBMC or umbilical cord blood cells were enriched for
CD34+ or CD3+ cells or depleted of CD3+, CD4+, CD8+ or CD25+ cells by
the magnetic cell sorting system (MACS) (Miltenyi Biotec, Bisley, Surrey,
UK). PBMC or T cells were labelled with CFSE as required (Sigma-Aldrich
Ltd, Gillingham, Dorset, UK). All procedures were performed according to
the manufacturer’s instructions.
Xenotransplantation and treatment
Animal studies were approved by the institutional ethics committee and
animals were treated in accordance with UK Home Office guidelines.
Primary CLL xenografts were generated following intravenous (i.v.)
injection of 0.1×107 to 10×107 CFSE-labelled (10 µM) patient PBMC cells
into γ-irradiated (1.25-2.5 Gy) NOG mice (5-9 weeks old) (in-house) either
upon evidence of engraftment (1% hCD45+ cells) of pre-injected 1×105
umbilical cord CD34+ cells in murine peripheral blood (cord blood model)
or concurrently with 1×105 allogeneic CD14+ cells (monocyte model)
(Bagnara et al., 2011).
Fluorescence-activated cell sorting (FACS) analysis
Single cell suspensions were labelled with various combinations of the
following fluorescently conjugated antibodies: murine (m)CD45, hCD45,
hCD19, hCD3, hCD8, hCCR7, hCD45-RA, hTIM3, hCD38, hPD-1
(eBioscience, Hatfield, Hertfordshire, UK), hCD4, hCD25 and hFoxP3
(BDBiosciences, Oxford, Oxfordshire, UK). Analysis was carried out using
an LSRII with FACS Diva software (BD, Oxford, Oxfordshire, UK). In
some cases, CountBright beads (Invitrogen, Paisley, Renfrewshire, UK)
were used to obtain absolute cell counts.
Fluorescence in situ hybridisation (FISH)
Several splenic regions were touched onto slides coated with poly-L-lysine,
fixed and air-dried. The following FISH probes were applied: CEP10,
CEP12 (Cytocell, Cambridge, Cambridgeshire, UK) and 11q (Abbott
Molecular, Maidenhead, UK). Hybridisations were performed with 2 min
denaturation at 73°C and 16 h incubation at 37°C on a HyBrite (Abbott
Molecular) and subsequent application of 4′6-diamidino-2-phenylindole
(DAPI) (Cytocell, Cambridge, Cambridgeshire, UK). Cells (>200/sample)
were visualised on an Olympus BX50 microscope (Southend-on-Sea,
Essex, UK).
Immunohistochemistry
Paraffin-embedded sections (5 µm) were stained with haematoxylin and
eosin (Sigma-Aldrich) and immunophenotyped using anti–human
antibodies against CD5, CD3, CD19, CD56 (Leica, Milton Keynes,
Buckinghamshire, UK), Pax5 (Thermo-Scientific, Loughborough,
Leicestershire, UK), Ki67, CD3, CD8 (Dako, Ely, Cambridgeshire, UK),
ATM (in-house), CD4, FoxP3, pPLCγ2 (Abcam, Cambridge,
Cambridgeshire, UK), CD20 (Spring Bioscience, Pleasanton, CA, USA),
p-ERK (Cell Signaling, Noston, MA, USA), PD-1, CD160 (Biorbyt,
Cambridge, Cambridgeshire, UK), CD244 (Novus Biologicals, Cambridge,
Cambridgeshire, UK) and an antibody against EBV transcript (Roche,
Burgess Hill, West Sussex, UK), following antigen retrieval with 10 mM
citrate buffer (Sigma-Aldrich). Where necessary, a mouse on mouse basic
kit (Vector Laboratories, Peterborough, Cambridgeshire, UK) was used
according to the manufacturer’s instructions. For dual-labelling of CD20
with pPLCγ2, after antigen retrieval the following reagents were
sequentially applied, being washed with 0.1% PBS-Tween-20 (Sigma-
Aldrich) after each application: blocking agent for 10 min (Vector
Laboratories), 1:500 CD20 antibody for 1 h and goat anti-rabbit HRP-
labelled IgG for 10 min (PerkinElmer, Waltham, MA, USA). Final
visualisation was with Opal™ cyanine 3 fluorophore (PerkinElmer). A
second round of antigen retrieval and staining was performed with pPLCg2
antibody (1:500) and Opal™ fluorescein visualisation, followed by
counterstaining of slides with DAPI (Life Technologies, Paisley,
Renfrewshire, UK).
Microsatellite analysis
DNA was extracted using a Flexigene kit (Qiagen, Manchester, Greater
Manchester, UK) and tested by multiplex PCR using 16 fluorescently
labelled primer sets (Nikolousis et al., 2013). Fluorescently labelled
products along with size standards were run on an ABI 3130 (PE Applied
Biosystems, Warrington, Cheshire, UK).
Cytotoxicity assay
Samples were enriched for B-CLL cells or xenograft-derived splenic T cells
via negative or positive selection with CD3+ MACS beads (Miltenyi
Biotec). CFSE-labelled (0.5 µM) splenic T cells were co-cultured with B-
CLL cells (1×105/well) at a ratio of 3:1 in RPMI media (Sigma-Aldrich)
containing 10% fetal calf serum (Sigma-Aldrich) and 10 U/ml recombinant
human IL-2 (PeproTech EC Ltd, London, Greater London, UK). After 24 h,
B-CLL number was quantified by FACS analysis (anti-hCD19, hCD3 and
hCD5; eBioscience, Hatfield, Hertfordshire, UK) with CountBright beads
(Invitrogen) (Fox et al., 2010; Hudecek et al., 2010).
Statistical analysis
Overall survival was compared by Kaplan–Meier curves and Mantel–Cox
log rank comparison with Gehan–Breslow–Wilcoxon correction test.
Engraftment levels were compared using an appropriate test for the
dataset (see figure legends). Statistical analysis was performed using
GraphPad Prism v6 (GraphPad Software, San Diego, CA, USA). Data are
presented as mean±s.e.m. (standard error of the mean).
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te Raa, G. D., Pascutti, M. F., Garcıá-Vallejo, J. J., Reinen, E., Remmerswaal,
E. B. M., ten Berge, I. J. M., van Lier, R. A. W., Eldering, E., van Oers, M. H. J.,
Tonino, S. H. et al. (2014). CMV-specific CD8+ T-cell function is not impaired in
chronic lymphocytic leukemia. Blood 123, 717-724.
ten Hacken, E. and Burger, J. A. (2014). Molecular pathways: targeting the
microenvironment in chronic lymphocytic leukemia–focus on the B-cell receptor.
Clin. Cancer Res. 20, 548-556.
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C.,
McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B.
et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in
cancer. N. Engl. J. Med. 366, 2443-2454.
Yang, Z.-Z., Novak, A. J., Ziesmar, S. C., Witzig, T. E. and Ansell, S. M. (2009).
Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell
non-Hodgkin’s lymphoma. Cancer Res. 69, 5522-5530.
Zanesi, N., Balatti, V., Riordan, J., Burch, A., Rizzotto, L., Palamarchuk, A.,
Cascione, L., Lagana, A., Dupuy, A. J., Croce, C. M. et al. (2013). A Sleeping
Beauty screen reveals NF-kB activation in CLL mouse model. Blood 121,
4355-4358.
Zhang, S. and Kipps, T. J. (2014). The pathogenesis of chronic lymphocytic
leukemia. Annu. Rev. Pathol. 9, 103-118.
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn,
D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K. et al. (2011).
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in
mice with disseminated acute myelogenous leukemia. Blood 117, 4501-4510.
1412
RESEARCH ARTICLE Disease Models & Mechanisms (2015) 8, 1401-1412 doi:10.1242/dmm.021147
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Supplementary data 
Table S1.  CLL patient details. 
Patient 
Diagnosis 
age, 
months 
Binet 
stage of 
sample 
used 
Lymphocyte 
doubling time, 
months 
Multiple 
treatments 
Biallelic loss 
of DNA 
damage 
response gene 
IgVH status 
Assigned 
classification at time 
of sample used 
QE87 51y 0mo A >12mo nt No M (V3-7/D6-6/J5-2) Indolent 
QE91 77y 5mo A >12mo nt No M (V3 1-3/3-21) Indolent 
QE14 57y 5mo A >12mo nt No M (V3-72/D5-24/J4-2) Indolent 
QE59 72y 5mo A >12mo Yes No M (V4-30.1) Indolent 
QE5 50y 0mo A >12mo nt No nk Indolent 
QE145 62y 0mo A >12mo nt No nk Indolent 
QE62 63y 8mo C <12mo nt* No M (V4 3-1) Progressive 
QEo24 61y 7mo B <12mo Yes ATM UM (V1-69) Progressive 
H438 63y 7mo B nk Yes No M (VH 3-23) Progressive 
QE18 62y 6mo B nk Yes No M (V5-51/D4-17/J6-2) Progressive 
QE71 74y 6mo C <12mo Yes No M (V3 1-1/3-66) Progressive 
QE147 83y 9mo B <12mo nt* TP53 nk Progressive** 
H289 65y 5mo B nk Yes ATM UM (VH 4-61) Progressive 
QE44 51y 11mo C <12mo Yes No M (VH3-23) Progressive*** 
H152 68y 6mo C nk Yes No UM (VH1-21) Progressive 
CLLs were assigned into two broad groups; indolent or progressive; based upon the guidelines of 
the British Committee for standards in Haematology.  Note: nt indicates not treated; M, mutated; 
nk, not known; UM, unmutated.  Classified as progressive due to: *Died of disease before 
treatment could be commenced; **17p
-
/p53mut status; ***Richters transformation.
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Table S2.  Xenograft experimental details. 
Expt CLL 
Xenograft 
model 
Depletion, 
%: 
PBMC, 
x107 
No. 
of 
mice, 
M/F 
Median 
overall 
survival, 
days 
Onset of 
T-cell 
outgrowth, 
weeks 
Terminal engraftment, % 
(mean ± s.e.m.) 
Splenic Bone marrow 
CLL 
hCD45 
T-cell 
of hCD45 
CLL 
hCD45 
T-cell 
of hCD45 
Xeno1 QEo24 CB nd 0.5 4 >32 4 83.3±87.4 3.7±2.1 21.6±8.2 2.1±1.2 
Xeno2 QEo24 CD14+ nd 0.5 4 >19 2-3 23.9±5.9 2.9±2.9 0.9±0.2 4.9±2.5 
Xeno3 H438 CB nd 5 2 M 35 3 96.0±0.7 62.8±31.9 23.6±3.8 15.2±5.1 
89% CD3 5 3 M 41 3-4 66.1±4.4 37.9±24.7 48.3±13.7 18.9±11.1 
98% CD3 5 3 M 73 6-7 16.9±9.7 46.6±21.2 16.9±9.7 14.3±6.3 
QE87 CB nd 5 1 M 29 3 97.4 63.3 46.0 77.9 
50% CD3 5 1 M 30 3 88.3 4.2 69.4 10.9 
98% CD3 5 1 M 55 6 0.2 17.6 0.2 20.2 
Xeno4 QE87 CD14+ nd 10 3 F 38 2 62.4±16.3 76.2±7.9 6.4±0.0 28.5±6.3 
Xeno5 H438 CB nd 2 2 M 50.5 nd 37.8±37.6 62.3±5.2 20.1±20.1 13.7±13.7 
100% CD8 2 1 M 99 0.6 55.6 2.9 8.8 
58% CD4 2 2 M 30.5 78 19.7 32.5 11.2 
73% CD3 2 1 M 34 79.9 7.6 70.2 6.9 
QE87 CB nd 2 1 M 35 nd nd nd nd nd 
100% CD8 2 1 M 99 87.6 33.6 60.1 10.7 
51% CD4 2 1 M 21 81.3 39.1 3.0 68.1 
80% CD3 2 1 M 26 0.8 68.2 2.8 5.6 
Xeno6 QE18 CB nd 1.3 3 F 55 nd nd nd nd nd 
75% CD3 1.3 3 F 47 50.7 6.4 62.5 6.5 
95% CD3 1.3 3 F 176 64.1±13.2 27.0±1.2 22.6±0.2 4.9±0.9 
QE71 CB nd 1.5 3 F 41 nd 70.6±16.5 29.3±2.2 50.1±25.1 22.1±2.2 
98% CD3 1.5 3 F 217 27.2±11.3 30.4±13.0 24.3±5.4 21.4±13.5 
Xeno7 H438 CB nd 0.2 3 M 158 9 33.7±8.2 12.8±4.2 30.0±1.3 3.0±1.0 
1 3 M 163 7 64.9±11.7 44.8±24 44.4±11.5 27.1±6.0 
5 2 M 41 nd 37.2 4 16.4 5.7 
QE87 CB nd 0.2 1 M 195 22 42.3 40.9 7.1 15.1 
1.8 1 M 57 7 92.7 14.6 58.8 2.2 
Xeno8 QE91 CB nd 8 2 F 106.5 4,12,20 25.7±21.7 7.2±3.2 3.6±3.2 11.0±5.9 
97% CD8 10 2 F 55.5 4 42.8 75.9 9.0 91.4 
76% CD4 8 2 F >252 18 nd nd nd nd 
95% CD3 8 2 F >252 6,18 nd nd nd nd 
QE14 CB nd 8 3 F 194 12 22.7±19 6.8±2.9 32.6±30.6 2.3±0.7 
92% CD8 10 2 M 102 18 47.5±25.8 58.3±22.9 12.2±1.3 44.2±36.3 
39% CD4 9 3 F 195 4,12,18 67.3±12.0 49.2±5.2 22.1 ± 3.9 29.0±10.9 
100% CD25 8 3 M >199.5 6,18 26 18.5 9.4 4.6 
52% CD3 8 3 F 128 6,12,18 55.3±10.0 20.4±18.6 27.8±10.9 10.9±8.4 
Xeno10 QE147 CB nd 10 1 M 126 4 66 41.2 13.2 20.6 
100% CD8 10 2 M 238 2 18.8±18.7 66.2±33.8 3.5±3.4 63.9±36.1 
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Expt CLL 
Xenograft 
model 
Depletion, 
%: 
PBMC, 
x107 
No. 
of 
mice, 
M/F 
Median 
overall 
survival, 
days 
Onset of 
T-cell 
outgrowth, 
weeks 
Terminal engraftment, % 
(mean ± s.e.m.) 
Splenic Bone marrow 
CLL 
hCD45 
T-cell 
of hCD45 
CLL 
hCD45 
T-cell 
of hCD45 
77% CD4 10 2 M 124.5 4 33.9 68.9 23.2 23.2 
42% CD25 0.5 2 M 123.5 4 12.8±10.8 21.8±15.7 8.9±5.5 52.2±11.6 
78% CD3 4.7 1 M 162 4 8.5 37.0 21.5 66.7 
QE59 CB nd 10 1 M 190 2 2.9 95.9 0.9 89.4 
100% CD8 3.6 2 M 204 4 51±41.9 83.8±5.4 24.7±2.5 81.2±13.4 
34% CD4 7.1 2 M 305 4 34.4±34.1 86.1±13.7 4.9±4.0 93.3±6.7 
55% CD25 0.9 2 M 229 4 6.1±4.1 65.7±21.3 7.9±7.6 69.1±6.8 
51% CD3 4.3 1 M 190 2 1.8 1.8 1.0 79.0 
Xeno15 QE5 CB nd 0.5 3 F 512 nd nd nd nd nd 
CD14+ nd 0.5 3 F 539 nd 31.7 8.7 4.5 20.9 
Xeno17 QE145 CD14+ nd 4 3 M 320 nd nd nd nd nd 
63% CD3 4 3 M 453 nd nd nd nd nd 
Xeno19 H289 CB CD3 0.5 4 M * nd 3.1±0.7 41.2±8.0 0.8±0.0 33.3±6.3 
Xeno20 QE62 CB nd 2 4 M 
4 F 
* nd nd nd nd nd 
98% CD3 0.3 4 M 
4 F 
* nd nd nd nd nd 
CD14+ nd 2 4 M 
4 F 
* nd nd nd nd nd 
95% CD3 0.3 4 M 
4 F 
* nd nd nd nd nd 
Xeno21 QE44 CD14+ nd 3.1 1 M 
7 F 
* nd nd nd nd nd 
Xeno22 H152 CB nd 0.2 4 M 
4 F 
* nd 11.9 56.4 75.4 9.2 
71% CD3 0.1 4 M 
4 F 
* nd 1.8 9.3 1.4 70.9 
CD14+ nd 0.2 4 M 
4 F 
* nd nd nd nd nd 
71% CD3 0.1 4 M 
4 F 
* nd 0.0 50.0 2.3 100.0 
Note: CB indicates cord blood model; nd, not done; CD14
+
, monocyte model; M, male; F,
female.  *Experimental end-point at a fixed time-point. 
Figure S1.  Peripheral blood engraftment levels do not reflect splenic engraftment.  FACS 
analysis following the kinetics of a single CLL (2x10
7
 PBMCs) engrafting in the spleen, bone
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marrow (BM) and peripheral blood in the monocyte model.  Each time-point depicts a specific 
week from a single animal.  We found that neither hCD45
+
 nor CLL (hCD45
+
CD3
-
) peripheral
blood engraftment is a good indicator of splenic engraftment levels. 
Figure S2.  Proliferation of CLL cells in primary CLL xenografts as evidenced by CFSE 
staining.  Injected CFSE labelled patient PBMCs demonstrated diminishing CFSE intensity of 
both the B- and T-cells upon xenotransplantation indicating proliferation of the primary CLL 
cells.  As cells proliferate, CFSE loses its intensity which is represented in the histograms as a 
shift of the peak towards the left hand side.  The bi-exponential display dot plots show the CFSE 
positivity of the B- (lower half) and T-cells (upper half).  Representative FACS plots following 
the progression of CLL throughout its course in a single animal are presented. 
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Figure S3.  Origin of human T-cells in the CD34
+
 humanised primary CLL xenograft
model.  (A) FACS analysis of engrafted cells indicates that at least a proportion of T-cells are of 
CLL origin as they retain CFSE from injected CLL PBMC.  Data presented as mean ± s.e.m. 
from 2 CLLs injected into 3 mice.  Data were compared using one-way ANOVA with Tukey 
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post-test and statistical significance denoted by: *
,†,‡
P≤0.05 (* CFSE-, † CFSE+, ‡ hCD3
engraftment). 
(B) Microsatellite analysis was employed to discern the origin of outgrowing T-cells.  DNA from 
CLL engrafted murine spleens along with the corresponding CLL PBMCs and supporting 
umbilical cord CD34
+
 cells were compared according to standard procedures (Skowronska et al.,
2012).  Various degrees of T-cell chimerism were detected even between mice injected with the 
same CLL cells (QE71) demonstrating the variation and mixed origin observed from four CLL 
samples.  Also, there was no evident relationship between T-cell chimerism levels and either 
input or splenic CD4:CD8 ratios or alterations of relative splenic T-cell subset levels vs input in 
this small cohort.  m: mouse number 1-3. 
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Figure S4.  Absence of GvHD.  Representative micrographs of haematoxylin and eosin stained 
CLL engrafted murine spleens display normal morphology and lack typical features of GvHD.  
Organs presented with normal morphology with an absence of infiltrating lymphocytes.  
Furthermore, there was no evidence of typical markers of GvHD such as inflammation of the 
skin or eyes (blepharitis and conjunctivitis), colitis or florid changes in the lung e.g. dense 
lymphocytic and macrophage-rich infiltrate sheathing the bronchi and pulmonary arteries which 
would result in the destruction and engulfment of the smooth muscle in the adventitia.  Nor did 
we observe any evidence of liver fibrosis, cholestasis, damage to the biliary epithelium and liver 
vessels or increased apoptosis of hepatocytes.  Images were captured by the Leica DMLB 
microscope with a Leica DFC320 camera microscope (Milton Keynes, Buckinghamshire, UK) at 
x10 magnification prior to article production. 
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Figure S5.  Retention of CD4:CD8 ratios.  FACS analysis quantification reveals that the 
CD4:CD8 ratios (median 0.20 vs 0.63) of T-cells derived from terminally engrafted spleens 
(Splenic: 7 CLL, 13 mice) from the cord blood model were within the normal range for CLL 
(Nunes et al., 2012) and not significantly different from the CLL PBMCs (Input: 7 CLL).  
CD4:CD8 ratios were compared using Wilcoxon matched pairs test and statistical significance 
denoted by: *P≤0.05. 
Figure S6.  Kinetics of CLL engraftment in the CD14
+
 supported model.  Mice were co-
injected with CD14
+
 monocytes from a single source along with PBMCs from one of 3
progressive CLL patients (n=8 mice/CLL, 1.8±0.9x10
7
 PBMC/animal).  Two of the same CLLs
were injected in a further cohort with prior reduction of patient T-cells by magnetic separation 
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(n=8 mice/CLL, 0.2±0.1x10
7
 PBMC/animal, 17±12% T-cells remaining).  A single animal from
each cohort was sacrificed on a bi-weekly basis for 20 weeks and splenic cell composition 
analyzed by FACs.  Terminal engraftment had not been reached by this time-point.  This 
revealed that: (i) T-cell depletion does not extend overall survival by delaying CLL proliferation 
and therefore does extend the engraftment window.  (ii) The proliferation of T-cells does not 
result in loss of CLL cells highlighting the interaction between these two populations.  (iii) T-cell 
depletion delays the initial cycle of the onset of T-cell growth indicating the dynamic nature of 
T-cells in CLL.  (iv) Percentage engraftment levels do not reflect the actual cell numbers present.  
Engraftment levels were compared using a one-way ANOVA with Dunnets post-test vs Input or 
two-way ANOVA with Bonferroni post-test vs Week 2 and statistical significance denoted by: 
+,†,‡
P≤0.05 vs Week 2 (+ B-cell, † T-cell, ‡ hCD45 engraftment), *P≤0.05 vs Non dep. 
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